Search
Methylparaben
go.drugbank.com/drugs/DB14212ApprovedMethylparaben is used in allergenic testing.
Categories: Compounds used in a research, industrial, or household settingTirbanibulin
go.drugbank.com/drugs/DB06137ApprovedInvestigationalTirbanibulin exhibits antitumour effects in vitro and in vivo [A225791] and has been investigated for its antitumor efficacy in the management of various cancers, such as prostate cancer and breast cancer … [A225726] On December 14, 2020, tirbanibulin was approved by the FDA for the topical treatment of actinic keratosis on the face or scalp. It is marketed under the brand name Klisyri.
Human calcitonin
go.drugbank.com/drugs/DB06773ApprovedCalcitonin was first discovered in isolated parathyroid tissue as a substance with a serum-calcium-lowering effect. … [A32098] It is used as an alternative for people developing antibodies against salmon calcitonin.[A32100]
Acitretin
go.drugbank.com/drugs/DB00459ApprovedInvestigationalAn oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate.
Synonyms: (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acidIdecabtagene vicleucel
go.drugbank.com/drugs/DB16665ApprovedInvestigational[L32858] Idecabtagene vicleucel was approved by the FDA on March 26, 2021 [L32863] and by the EMA on August 18, 2021.[L51003] … [A232563] Multiple myeloma is typically treated with an immunomodulatory agent like [lenalidomide],[A232593] a proteasome inhibitor like [bortezomib], or an anti-CD38 monoclonal antibody like [isatuximab
Lumateperone
go.drugbank.com/drugs/DB06077ApprovedInvestigationalSchizophrenia is a complex mental illness and impacts approximately 1% of the population. … [A189093] Further, not only is the new antipsychotic selective for dopamine (D2) receptors in the mesolimbic and mesocortical brain regions, but it also has minimal off-target activity.
Bromfenac
go.drugbank.com/drugs/DB00963ApprovedWithdrawnNon-ophthalmic formulations of bromfenac were withdrawn in the US in 1998 due to cases of severe liver toxicity.[L43942,T239] … Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool for optimizing surgical outcomes.
Palopegteriparatide
go.drugbank.com/drugs/DB18676ApprovedInvestigational[L51134] PTH(1-34) contains the N-terminal part of the endogenous PTH molecule. … [L51134] Palopegteriparatide was first approved by the EMA on November 17, 2023, for the treatment of hyperparathyroidism.[L51134] On August 8, 2024, palopegteriparatide was also approved by the FDA.
Synonyms: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34, Poly(oxy-1,2-ethanediyl), α-hydro-ω-methoxy-, ether with N-[[[2-[[6-[[1-[3-[[3-(2,3-dihydroxypropoxy)propyl]amino]-3-oxopropyl]-2,5-dioxo-3-pyrrolidinyl]thio]hexyl]amino]ethyl]amino]carbonyl]-2-methylalanyl-L-seryl-L-valyl-L-seryl-L-α-glutamyl-L-isoleNADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial
go.drugbank.com/bio_entities/BE0000027TargetHumansMay be the terminally assembled subunit of Complex I … Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis.
Synonyms: Complex I-9kDNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 12
go.drugbank.com/bio_entities/BE0000754TargetHumansAccessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. … Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone
Synonyms: Complex I-B17.2